Sichuan Biokin Pharmaceutical (688506.SH): Clinical trial of injectable BL-M24D1 (ADC) drug approved.

Sichuan Biokin Pharmaceutical (688506.SH) announced that the company has recently received the official approval from the National Medical Products Administration (NMPA) for the issuance of the "Drug Clinical Trial Approval Notice" for the company's independently developed innovative biopharmaceutical injection BL-M24D1 (ADC) for clinical trials. BL-M24D1 is an ADC drug independently developed by the company, which is coupled with a new generation toxin. It comes from the same small molecule technology platform as BL-B16D1 and BL-M17D1, and shares the same "linker + toxin" platform. Its indications are recurrent or refractory hematologic malignancies and advanced solid tumors.